Financial Data and Key Metrics Changes - The company's turnover increased by 1% to R9.8 billion for the year, with a notable recovery in the second half driven by strong demand and improved operational performance [4][30] - Trading profit declined by 4% to R1.18 billion, recovering from a 17% decline reported at the half-year mark [6][33] - Headline earnings per share increased by 1.5% to 625.6 cents, supported by solid contributions from joint ventures and share repurchase impacts [6][35] Business Line Data and Key Metrics Changes - The Consumer division saw a 6% increase in trading profit, driven by strong performance in personal and home care products, particularly the EpiMax brand [12][41] - The Over-the-Counter (OTC) division's trading profit increased by 5% to R404 million, benefiting from an early flu season and normalized buying patterns [16][43] - The Prescription division's trading profit decreased by 25% to R265 million, although it showed recovery from a 52% decline at the half-year [18][45] - The Hospital division's revenue increased by 6.7% to R2.2 billion, supported by increased demand for renal products and intravenous fluids [22][46] Market Data and Key Metrics Changes - The company reported a gross margin decline to 33%, down from 33.4% the previous year, influenced by a less favorable sales mix and lower production levels at the Wadeville facility [5][32] - The OTC division holds a market share of about 20% and a volume share of almost 30% in South Africa [13] Company Strategy and Development Direction - The company is focusing on integrating the Lundbeck portfolio to strengthen its presence in the central nervous system pharmaceuticals market [19][20] - A commercial agreement with GSK South Africa aims to introduce a pipeline of vaccines, starting with Bexera for meningitis B prevention [20] - The company is investing in infrastructure improvements and regulatory compliance to enhance operational resilience [24][27] Management's Comments on Operating Environment and Future Outlook - Management noted a marked improvement in trading and financial performance in the second half, driven by strong demand and disciplined cost management [4][6] - The regulatory environment remains stable, with updates on codeine-containing medicines and ongoing assessments for orally administered phenylephrine products [7][8] - The company is optimistic about future growth, particularly in the hospital and prescription divisions, despite challenges faced in the past year [18][22] Other Important Information - The company has made significant investments in sustainability initiatives, including waste management and renewable energy projects [25][26] - A ten-year supply and distribution agreement with Medline has been signed to enhance the hospital division's offerings [25] Q&A Session Summary Question: Are there any questions from the conference call? - There were no questions from the conference call or the webcast, indicating a comprehensive overview was provided [49][50]